Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Stage III Hypopharyngeal Carcinoma AJCC v7”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 0 results

Not applicableWithdrawnNCT05512767
What this trial is testing

A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation

Who this might be right for
Clinical Stage II HPV-Mediated (p16-pos) Oropharyngeal CarcinomaClinical Stage III HPV-Mediated (p16-pos) Oropharyngeal CarcinomaClinical Stage IV HPV-Mediated (p16-pos)Oropharyngeal Carcinoma+13 more
Mayo Clinic
Early research (Phase 1)Looking for participantsNCT07156227
What this trial is testing

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

Who this might be right for
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell Carcinoma+27 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Active Not RecruitingNCT00588770
What this trial is testing

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Neck Squamous Cell Carcinoma of Unknown PrimaryRecurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell Carcinoma+32 more
National Cancer Institute (NCI) 403
39